Advancement and applications of peptide phage display technology in biomedical science

Journal of Biomedical Science

Volumn 23, Issue 1, 2016, Pages

  Wu, Chien Hsun ^a   Liu, I Ju ^a   Lu, Ruei Min ^a   Wu, Han Chung ^a  

^a INSTITUTE OF CELLULAR AND ORGANISMIC BIOLOGY   (Taiwan)

Author keywords

Antigen mimics; Drug delivery; Epitope mapping; Peptides; Phage display

Indexed keywords

ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; GRN 1005; MEMBRANE RECEPTOR; NANOPARTICLE; PEPTIDE DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG; EPITOPE; PEPTIDE LIBRARY;

ANTIBODY DRUG CONJUGATE; ANTIBODY SPECIFICITY; B LYMPHOCYTE; BIOMEDICINE; BIOTECHNOLOGY; BRAIN METASTASIS; BREAST METASTASIS; CELL SPECIFICITY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; EPITOPE MAPPING; HUMAN; MOLECULAR MIMICRY; NONHUMAN; PEPTIDE DRUG CONJUGATE; PEPTIDE LIBRARY; PHAGE DISPLAY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; T LYMPHOCYTE; ANIMAL; CHEMISTRY; GENETICS; IMMUNOLOGY; MEDICAL RESEARCH; PROCEDURES;

ANIMALS; BIOMEDICAL RESEARCH; EPITOPES, B-LYMPHOCYTE; EPITOPES, T-LYMPHOCYTE; HUMANS; PEPTIDE LIBRARY;

EID: 84957439134     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/s12929-016-0223-x     Document Type: Review

References (147)

1. Smith GP. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science. 1985;228(4705):1315-7.
2. Huang J, Honda W. CED: a conformational epitope database. BMC Immunol. 2006;7:7.
3. Geysen HM, Meloen RH, Barteling SJ. Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid. Proc Natl Acad Sci U S A. 1984;81(13):3998-4002.
4. Lo Conte L, Chothia C, Janin J. The atomic structure of protein-protein recognition sites. J Mol Biol. 1999;285(5):2177-98.
5. Dummer R, Mittelman A, Fanizzi FP, Lucchese G, Willers J, Kanduc D. Non-self-discrimination as a driving concept in the identification of an immunodominant HMW-MAA epitopic peptide sequence by autoantibodies from melanoma cancer patients. Int J Cancer. 2004;111(5):720-6.
6. Kuntz ID, Blaney JM, Oatley SJ, Langridge R, Ferrin TE. A geometric approach to macromolecule-ligand interactions. J Mol Biol. 1982;161(2):269-88.
7. Benjamin DC, Perdue SS. Site-Directed Mutagenesis in Epitope Mapping. Methods. 1996;9(3):508-15.
8. Enshell-Seijffers D, Denisov D, Groisman B, Smelyanski L, Meyuhas R, Gross G, et al. The mapping and reconstitution of a conformational discontinuous B-cell epitope of HIV-1. J Mol Biol. 2003;334(1):87-101.
9. Oleksiewicz MB, Botner A, Toft P, Normann P, Storgaard T. Epitope mapping porcine reproductive and respiratory syndrome virus by phage display: the nsp2 fragment of the replicase polyprotein contains a cluster of B-cell epitopes. J Virol. 2001;75(7):3277-90.
10. Riemer AB, Kraml G, Scheiner O, Zielinski CC, Jensen-Jarolim E. Matching of trastuzumab (Herceptin) epitope mimics onto the surface of Her-2/neu - a new method of epitope definition. Mol Immunol. 2005;42(9):1121-4.
11. Chen YC, Huang HN, Lin CT, Chen YF, King CC, Wu HC. Generation and characterization of monoclonal antibodies against dengue virus type 1 for epitope mapping and serological detection by epitope-based peptide antigens. Clin Vaccine Immunol. 2007;14(4):404-11.
12. Wang X, Zhao Q, Dang L, Sun Y, Gao J, Liu B, et al. Characterization of Two Novel Linear B-Cell Epitopes in the Capsid Protein of Avian Hepatitis E Virus (HEV) That Are Common to Avian, Swine, and Human HEVs. J Virol. 2015;89(10):5491-501.
13. Wu HC, Huang YL, Chao TT, Jan JT, Huang JL, Chiang HY, et al. Identification of B-cell epitope of dengue virus type 1 and its application in diagnosis of patients. J Clin Microbiol. 2001;39(3):977-82.
14. Wu HC, Yeh CT, Huang YL, Tarn LJ, Lung CC. Characterization of neutralizing antibodies and identification of neutralizing epitope mimics on the Clostridium botulinum neurotoxin type A. Appl Environ Microbiol. 2001;67(7):3201-7.
15. Wu HC, Jung MY, Chiu CY, Chao TT, Lai SC, Jan JT, et al. Identification of a dengue virus type 2 (DEN-2) serotype-specific B-cell epitope and detection of DEN-2-immunized animal serum samples using an epitope-based peptide antigen. J Gen Virol. 2003;84(Pt 10):2771-9.
16. Li PC, Liao MY, Cheng PC, Liang JJ, Liu IJ, Chiu CY, et al. Development of a humanized antibody with high therapeutic potential against dengue virus type 2. PLoS Negl Trop Dis. 2012;6(5), e1636.
17. Liu IJ, Hsueh PR, Lin CT, Chiu CY, Kao CL, Liao MY, et al. Disease-specific B Cell epitopes for serum antibodies from patients with severe acute respiratory syndrome (SARS) and serologic detection of SARS antibodies by epitope-based peptide antigens. J Infect Dis. 2004;190(4):797-809.
18. Santamaria H, Manoutcharian K, Rocha L, Gonzalez E, Acero G, Govezensky T, et al. Identification of peptide sequences specific for serum antibodies from human papillomavirus-infected patients using phage display libraries. Clin Immunol. 2001;101(3):296-302.
19. Khurana S, Suguitan Jr AL, Rivera Y, Simmons CP, Lanzavecchia A, Sallusto F, et al. Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and diagnostic targets. PLoS Med. 2009;6(4), e1000049.
20. Zhou Z, Gao X, Wang Y, Zhou H, Wu C, Paranhos-Baccala G, et al. Conserved B-cell epitopes among human bocavirus species indicate potential diagnostic targets. PLoS One. 2014;9(1):e86960.
21. Malito E, Faleri A, Lo Surdo P, Veggi D, Maruggi G, Grassi E, et al. Defining a protective epitope on factor H binding protein, a key meningococcal virulence factor and vaccine antigen. Proc Natl Acad Sci U S A. 2013;110(9):3304-9.
22. Folgori A, Tafi R, Meola A, Felici F, Galfre G, Cortese R, et al. A general strategy to identify mimotopes of pathological antigens using only random peptide libraries and human sera. EMBO J. 1994;13(9):2236-43.
23. Prezzi C, Nuzzo M, Meola A, Delmastro P, Galfre G, Cortese R, et al. Selection of antigenic and immunogenic mimics of hepatitis C virus using sera from patients. J Immunol. 1996;156(11):4504-13.
24. Dybwad A, Forre O, Kjeldsen-Kragh J, Natvig JB, Sioud M. Identification of new B cell epitopes in the sera of rheumatoid arthritis patients using a random nanopeptide phage library. Eur J Immunol. 1993;23(12):3189-93.
25. Cortese I, Tafi R, Grimaldi LM, Martino G, Nicosia A, Cortese R. Identification of peptides specific for cerebrospinal fluid antibodies in multiple sclerosis by using phage libraries. Proc Natl Acad Sci U S A. 1996;93(20):11063-7.
26. Bowditch RD, Tani P, Fong KC, McMillan R. Characterization of autoantigenic epitopes on platelet glycoprotein IIb/IIIa using random peptide libraries. Blood. 1996;88(12):4579-84.
27. Gevorkian G, Manoutcharian K, Almagro JC, Govezensky T, Dominguez V. Identification of autoimmune thrombocytopenic purpura-related epitopes using phage-display peptide library. Clin Immunol Immunopathol. 1998;86(3):305-9.
28. Manoutcharian K, Sotelo J, Garcia E, Cano A, Gevorkian G. Characterization of cerebrospinal fluid antibody specificities in neurocysticercosis using phage display peptide library. Clin Immunol. 1999;91(1):117-21.
29. Chen Y, Luo W, Song H, Yin B, Tang J, Chen Y, et al. Mimotope ELISA for detection of broad spectrum antibody against avian H5N1 influenza virus. PLoS One. 2011;6(9), e24144.
30. Araujo GR, Vaz ER, Fujimura PT, Fonseca JE, de Lima LM, Canhao H, et al. Improved serological detection of rheumatoid arthritis: a highly antigenic mimotope of carbonic anhydrase III selected in a murine model by phage display. Arthritis Res Ther. 2015;17:168.
31. Yu RK, Usuki S, Itokazu Y, Wu HC. Novel GM1 ganglioside-like peptide mimics prevent the association of cholera toxin to human intestinal epithelial cells in vitro. Glycobiology. 2015.
32. Lunardi C, Bason C, Navone R, Millo E, Damonte G, Corrocher R, et al. Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells. Nat Med. 2000;6(10):1183-6.
33. Liu IJ, Chiu CY, Chen YC, Wu HC. Molecular mimicry of human endothelial cell antigen by autoantibodies to nonstructural protein 1 of dengue virus. J Biol Chem. 2011;286(11):9726-36.
34. Mintz PJ, Rietz AC, Cardo-Vila M, Ozawa MG, Dondossola E, Do KA, et al. Discovery and horizontal follow-up of an autoantibody signature in human prostate cancer. Proc Natl Acad Sci U S A. 2015;112(8):2515-20.
35. Arinaminpathy Y, Khurana E, Engelman DM, Gerstein MB. Computational analysis of membrane proteins: the largest class of drug targets. Drug Discov Today. 2009;14(23-24):1130-5.
36. Deller MC, Yvonne JE. Cell surface receptors. Curr Opin Struct Biol. 2000;10(2):213-9.
37. Wrighton NC, Farrell FX, Chang R, Kashyap AK, Barbone FP, Mulcahy LS, et al. Small peptides as potent mimetics of the protein hormone erythropoietin. Science. 1996;273(5274):458-64.
38. Cwirla SE, Balasubramanian P, Duffin DJ, Wagstrom CR, Gates CM, Singer SC, et al. Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Science. 1997;276(5319):1696-9.
39. Su JL, Lai KP, Chen CA, Yang CY, Chen PS, Chang CC, et al. A novel peptide specifically binding to interleukin-6 receptor (gp80) inhibits angiogenesis and tumor growth. Cancer Res. 2005;65(11):4827-35.
40. Hetian L, Ping A, Shumei S, Xiaoying L, Luowen H, Jian W, et al. A novel peptide isolated from a phage display library inhibits tumor growth and metastasis by blocking the binding of vascular endothelial growth factor to its kinase domain receptor. J Biol Chem. 2002;277(45):43137-42.
41. Yanofsky SD, Baldwin DN, Butler JH, Holden FR, Jacobs JW, Balasubramanian P, et al. High affinity type I interleukin 1 receptor antagonists discovered by screening recombinant peptide libraries. Proc Natl Acad Sci U S A. 1996;93(14):7381-6.
42. Heller T, Hennecke M, Baumann U, Gessner JE. zu Vilsendorf AM, Baensch M et al. Selection of a C5a receptor antagonist from phage libraries attenuating the inflammatory response in immune complex disease and ischemia/reperfusion injury. J Immunol. 1999;163(2):985-94.
43. Binetruy-Tournaire R, Demangel C, Malavaud B, Vassy R, Rouyre S, Kraemer M, et al. Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis. EMBO J. 2000;19(7):1525-33.
44. An P, Lei H, Zhang J, Song S, He L, Jin G, et al. Suppression of tumor growth and metastasis by a VEGFR-1 antagonizing peptide identified from a phage display library. Int J Cancer. 2004;111(2):165-73.
45. Houimel M, Mazzucchelli L. hCXCR1 and hCXCR2 antagonists derived from combinatorial peptide libraries. Cytokine. 2012;57(3):322-31.
46. Hessling J, Lohse MJ, Klotz KN. Peptide G protein agonists from a phage display library. Biochem Pharmacol. 2003;65(6):961-7.
47. Malik S, Ghosh M, Bonacci TM, Tall GG, Smrcka AV. Ric-8 enhances G protein betagamma-dependent signaling in response to betagamma-binding peptides in intact cells. Mol Pharmacol. 2005;68(1):129-36.
48. Diamond SL. Methods for mapping protease specificity. Curr Opin Chem Biol. 2007;11(1):46-51.
49. Kehoe JW, Kay BK. Filamentous phage display in the new millennium. Chem Rev. 2005;105(11):4056-72.
50. Zani ML, Moreau T. Phage display as a powerful tool to engineer protease inhibitors. Biochimie. 2010;92(11):1689-704.
51. Bahudhanapati H, Zhang Y, Sidhu SS, Brew K. Phage display of tissue inhibitor of metalloproteinases-2 (TIMP-2): identification of selective inhibitors of collagenase-1 (metalloproteinase 1 (MMP-1)). J Biol Chem. 2011;286(36):31761-70.
52. Lin SH, Chang DK, Chou MJ, Huang KJ, Shiuan D. Peptide inhibitors of human HMG-CoA reductase as potential hypocholesterolemia agents. Biochem Biophys Res Commun. 2015;456(1):104-9.
53. Mund T, Lewis MJ, Maslen S, Pelham HR. Peptide and small molecule inhibitors of HECT-type ubiquitin ligases. Proc Natl Acad Sci U S A. 2014;111(47):16736-41.
54. Lee YC, Hsiao NW, Tseng TS, Chen WC, Lin HH, Leu SJ, et al. Phage display-mediated discovery of novel tyrosinase-targeting tetrapeptide inhibitors reveals the significance of N-terminal preference of cysteine residues and their functional sulfur atom. Mol Pharmacol. 2015;87(2):218-30.
55. Hertveldt K, Belien T, Volckaert G. General M13 phage display: M13 phage display in identification and characterization of protein-protein interactions. Methods Mol Biol. 2009;502:321-39.
56. Fuh G, Pisabarro MT, Li Y, Quan C, Lasky LA, Sidhu SS. Analysis of PDZ domain-ligand interactions using carboxyl-terminal phage display. J Biol Chem. 2000;275(28):21486-91.
57. James KJ, Hancock MA, Gagnon JN, Coulton JW. TonB interacts with BtuF, the Escherichia coli periplasmic binding protein for cyanocobalamin. Biochemistry. 2009;48(39):9212-20.
58. Caberoy NB, Zhou Y, Jiang X, Alvarado G, Li W. Efficient identification of tubby-binding proteins by an improved system of T7 phage display. J Mol Recognit. 2010;23(1):74-83.
59. Karkkainen S, Hiipakka M, Wang JH, Kleino I, Vaha-Jaakkola M, Renkema GH, et al. Identification of preferred protein interactions by phage-display of the human Src homology-3 proteome. EMBO Rep. 2006;7(2):186-91.
60. Voss M, Lettau M, Janssen O. Identification of SH3 domain interaction partners of human FasL (CD178) by phage display screening. BMC Immunol. 2009;10:53.
61. Kofler M, Motzny K, Beyermann M, Freund C. Novel interaction partners of the CD2BP2-GYF domain. J Biol Chem. 2005;280(39):33397-402.
62. Abu-Odeh M, Bar-Mag T, Huang H, Kim T, Salah Z, Abdeen SK, et al. Characterizing WW domain interactions of tumor suppressor WWOX reveals its association with multiprotein networks. J Biol Chem. 2014;289(13):8865-80.
63. Forster-Waldl E, Riemer AB, Dehof AK, Neumann D, Bramswig K, Boltz-Nitulescu G, et al. Isolation and structural analysis of peptide mimotopes for the disialoganglioside GD2, a neuroblastoma tumor antigen. Mol Immunol. 2005;42(3):319-25.
64. Peng Y, Zhang Y, Mitchell WJ, Zhang G. Development of a lipopolysaccharide-targeted peptide mimic vaccine against Q fever. J Immunol. 2012;189(10):4909-20.
65. Naz RK. Status of contraceptive vaccines. Am J Reprod Immunol. 2009;61(1):11-8.
66. Knittelfelder R, Riemer AB, Jensen-Jarolim E. Mimotope vaccination - from allergy to cancer. Expert Opin Biol Ther. 2009;9(4):493-506.
67. Lamichhane TN, Abeydeera ND, Duc AC, Cunningham PR, Chow CS. Selection of peptides targeting helix 31 of bacterial 16S ribosomal RNA by screening M13 phage-display libraries. Molecules. 2011;16(2):1211-39.
68. Li M, Duc AC, Klosi E, Pattabiraman S, Spaller MR, Chow CS. Selection of peptides that target the aminoacyl-tRNA site of bacterial 16S ribosomal RNA. Biochemistry. 2009;48(35):8299-311.
69. Bose D, Nahar S, Rai MK, Ray A, Chakraborty K, Maiti S. Selective inhibition of miR-21 by phage display screened peptide. Nucleic Acids Res. 2015;43(8):4342-52.
70. Rozinov MN, Nolan GP. Evolution of peptides that modulate the spectral qualities of bound, small-molecule fluorophores. Chem Biol. 1998;5(12):713-28.
71. Zhao SW, Shen PP, Zhou Y, Wei Y, Xin XB, Hua ZC. Selecting peptide ligands of microcystin-LR from phage displayed random libraries. Environ Int. 2005;31(4):535-41.
72. Aoki S, Morohashi K, Sunoki T, Kuramochi K, Kobayashi S, Sugawara F. Screening of paclitaxel-binding molecules from a library of random peptides displayed on T7 phage particles using paclitaxel-photoimmobilized resin. Bioconjug Chem. 2007;18(6):1981-6.
73. Liu Z, Liu J, Wang K, Li W, Shelver WL, Li QX, et al. Selection of phage-displayed peptides for the detection of imidacloprid in water and soil. Anal Biochem. 2015;485:28-33.
74. Seker UOS, Demir HV. Material Binding Peptides for Nanotechnology. Molecules. 2011;16(2):1426.
75. Whaley SR, English DS, Hu EL, Barbara PF, Belcher AM. Selection of peptides with semiconductor binding specificity for directed nanocrystal assembly. Nature. 2000;405(6787):665-8.
76. Mao C, Flynn CE, Hayhurst A, Sweeney R, Qi J, Georgiou G, et al. Viral assembly of oriented quantum dot nanowires. Proc Natl Acad Sci U S A. 2003;100(12):6946-51.
77. Naik RR, Brott LL, Clarson SJ, Stone MO. Silica-precipitating peptides isolated from a combinatorial phage display peptide library. J Nanosci Nanotechnol. 2002;2(1):95-100.
78. Brown S. Engineered iron oxide-adhesion mutants of the Escherichia coli phage lambda receptor. Proc Natl Acad Sci U S A. 1992;89(18):8651-5.
79. Chen H, Su X, Neoh KG, Choe WS. QCM-D analysis of binding mechanism of phage particles displaying a constrained heptapeptide with specific affinity to SiO2 and TiO2. Anal Chem. 2006;78(14):4872-9.
80. Sanghvi AB, Miller KPH, Belcher AM, Schmidt CE. Biomaterials functionalization using a novel peptide that selectively binds to a conducting polymer. Nat Mater. 2005;4(6):496-502.
81. Naik RR, Stringer SJ, Agarwal G, Jones SE, Stone MO. Biomimetic synthesis and patterning of silver nanoparticles. Nat Mater. 2002;1(3):169-72.
82. Brown S. Metal-recognition by repeating polypeptides. Nat Biotechnol. 1997;15(3):269-72.
83. Sano K, Sasaki H, Shiba K. Specificity and biomineralization activities of Ti-binding peptide-1 (TBP-1). Langmuir. 2005;21(7):3090-5.
84. Sarikaya M, Tamerler C, Jen AK, Schulten K, Baneyx F. Molecular biomimetics: nanotechnology through biology. Nat Mater. 2003;2(9):577-85.
85. Barry MA, Dower WJ, Johnston SA. Toward cell-targeting gene therapy vectors: selection of cell-binding peptides from random peptide-presenting phage libraries. Nat Med. 1996;2(3):299-305.
86. Lo A, Lin CT, Wu HC. Hepatocellular carcinoma cell-specific peptide ligand for targeted drug delivery. Mol Cancer Ther. 2008;7(3):579-89.
87. Lee TY, Wu HC, Tseng YL, Lin CT. A novel peptide specifically binding to nasopharyngeal carcinoma for targeted drug delivery. Cancer Res. 2004;64(21):8002-8.
88. Chang DK, Lin CT, Wu CH, Wu HC. A novel peptide enhances therapeutic efficacy of liposomal anti-cancer drugs in mice models of human lung cancer. PLoS One. 2009;4(1):e4171.
89. Wu CH, Kuo YH, Hong RL, Wu HC. alpha-Enolase-binding peptide enhances drug delivery efficiency and therapeutic efficacy against colorectal cancer. Sci Transl Med. 2015;7(290):290ra91.
90. Lu RM, Chen MS, Chang DK, Chiu CY, Lin WC, Yan SL, et al. Targeted drug delivery systems mediated by a novel Peptide in breast cancer therapy and imaging. PLoS One. 2013;8(6), e66128.
91. Gray BP, Brown KC. Combinatorial peptide libraries: mining for cell-binding peptides. Chem Rev. 2014;114(2):1020-81.
92. Lunder M, Bratkovic T, Urleb U, Kreft S, Strukelj B. Ultrasound in phage display: a new approach to nonspecific elution. Biotechniques. 2008;44(7):893-900.
93. Gray BP, Li S, Brown KC. From phage display to nanoparticle delivery: functionalizing liposomes with multivalent peptides improves targeting to a cancer biomarker. Bioconjug Chem. 2013;24(1):85-96.
94. Brown KC. Peptidic tumor targeting agents: the road from phage display peptide selections to clinical applications. Curr Pharm Des. 2010;16(9):1040-54.
95. Pasqualini R, Ruoslahti E. Organ targeting in vivo using phage display peptide libraries. Nature. 1996;380(6572):364-6.
96. Laakkonen P, Porkka K, Hoffman JA, Ruoslahti E. A tumor-homing peptide with a targeting specificity related to lymphatic vessels. Nat Med. 2002;8(7):751-5.
97. Lee TY, Lin CT, Kuo SY, Chang DK, Wu HC. Peptide-mediated targeting to tumor blood vessels of lung cancer for drug delivery. Cancer Res. 2007;67(22):10958-65.
98. Molenaar TJ, Michon I, de Haas SA, van Berkel TJ, Kuiper J, Biessen EA. Uptake and processing of modified bacteriophage M13 in mice: implications for phage display. Virology. 2002;293(1):182-91.
99. Zou J, Dickerson MT, Owen NK, Landon LA, Deutscher SL. Biodistribution of filamentous phage peptide libraries in mice. Mol Biol Rep. 2004;31(2):121-9.
100. Rajotte D, Arap W, Hagedorn M, Koivunen E, Pasqualini R, Ruoslahti E. Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. J Clin Invest. 1998;102(2):430-7.
101. Babickova J, Tothova L, Boor P, Celec P. In vivo phage display - a discovery tool in molecular biomedicine. Biotechnol Adv. 2013;31(8):1247-59.
102. Krumpe LR, Mori T. The Use of Phage-Displayed Peptide Libraries to Develop Tumor-Targeting Drugs. Int J Pept Res Ther. 2006;12(1):79-91.
103. Mori T. Cancer-specific ligands identified from screening of peptide-display libraries. Curr Pharm Des. 2004;10(19):2335-43.
104. Rafii S, Avecilla ST, Jin DK. Tumor vasculature address book: identification of stage-specific tumor vessel zip codes by phage display. Cancer Cell. 2003;4(5):331-3.
105. Chang DK, Chiu CY, Kuo SY, Lin WC, Lo A, Wang YP, et al. Antiangiogenic targeting liposomes increase therapeutic efficacy for solid tumors. J Biol Chem. 2009;284(19):12905-16.
106. Laakkonen P, Zhang L, Ruoslahti E. Peptide targeting of tumor lymph vessels. Ann N Y Acad Sci. 2008;1131:37-43.
107. Arap W, Kolonin MG, Trepel M, Lahdenranta J, Cardo-Vila M, Giordano RJ, et al. Steps toward mapping the human vasculature by phage display. Nat Med. 2002;8(2):121-7.
108. Krag DN, Shukla GS, Shen GP, Pero S, Ashikaga T, Fuller S, et al. Selection of tumor-binding ligands in cancer patients with phage display libraries. Cancer Res. 2006;66(15):7724-33.
109. Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer. 2002;2(10):750-63.
110. Bolotin EM, Cohen R, Bar LK, Emanuel N, Ninio S, Barenholz Y, et al. Ammonium Sulfate Gradients for Efficient and Stable Remote Loading of Amphipathic Weak Bases into Liposomes and Ligandoliposomes. J Liposome Res. 1994;4(1):455-79.
111. Boman NL, Bally MB, Cullis PR, Mayer LD, Webb MS. Encapsulation of Vincristine in Liposomes Reduces its Toxicity and Improves its Anti-Tumor Efficacy. J Liposome Res. 1995;5(3):523-41.
112. Jain RK. Transport of molecules in the tumor interstitium: a review. Cancer Res. 1987;47(12):3039-51.
113. Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer. 2004;4(10):806-13.
114. Wu H-C, Chang D-K, Huang C-T. Targeted therapy for cancer. J Cancer Mol. 2006;2(2):57-66.
115. Harding JA, Engbers CM, Newman MS, Goldstein NI, Zalipsky S. Immunogenicity and pharmacokinetic attributes of poly(ethylene glycol)-grafted immunoliposomes. Biochim Biophys Acta. 1997;1327(2):181-92.
116. Koning GA, Kamps JA, Scherphof GL. Interference of macrophages with immunotargeting of liposomes. J Liposome Res. 2002;12(1-2):107-19.
117. ElBayoumi TA, Torchilin VP. Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody. Clin Cancer Res. 2009;15(6):1973-80.
118. Liu Z, Cai W, He L, Nakayama N, Chen K, Sun X, et al. In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nat Nanotechnol. 2007;2(1):47-52.
119. Qian X, Peng XH, Ansari DO, Yin-Goen Q, Chen GZ, Shin DM, et al. In vivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags. Nat Biotechnol. 2008;26(1):83-90.
120. Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 2006;66(13):6732-40.
121. Bartlett DW, Su H, Hildebrandt IJ, Weber WA, Davis ME. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci U S A. 2007;104(39):15549-54.
122. Moghimi SM, Hunter AC, Andresen TL. Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective. Annu Rev Pharmacol Toxicol. 2012;52:481-503.
123. Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, Alpaugh RK, et al. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res. 2001;61(12):4750-5.
124. Rudnick SI, Lou J, Shaller CC, Tang Y, Klein-Szanto AJ, Weiner LM, et al. Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors. Cancer Res. 2011;71(6):2250-9.
125. Tian F, Tsao ML, Schultz PG. A phage display system with unnatural amino acids. J Am Chem Soc. 2004;126(49):15962-3.
126. Sandman KE, Benner JS, Noren CJ. Phage Display of Selenopeptides. J Am Chem Soc. 2000;122(5):960-1.
127. Woiwode TF, Haggerty JE, Katz R, Gallop MA, Barrett RW, Dower WJ, et al. Synthetic compound libraries displayed on the surface of encoded bacteriophage. Chem Biol. 2003;10(9):847-58.
128. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol. 2008;26(11):1789-96.
129. Bibeau F, Lopez-Crapez E, Di Fiore F, Thezenas S, Ychou M, Blanchard F, et al. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol. 2009;27(7):1122-9.
130. Firer MA, Gellerman G. Targeted drug delivery for cancer therapy: the other side of antibodies. J Hematol Oncol. 2012;5:70.
131. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 1998;279(5349):377-80.
132. Burkhart DJ, Kalet BT, Coleman MP, Post GC, Koch TH. Doxorubicin-formaldehyde conjugates targeting alphavbeta3 integrin. Mol Cancer Ther. 2004;3(12):1593-604.
133. Li X, Hou J, Wang C, Liu X, He H, Xu P, et al. Synthesis and biological evaluation of RGD-conjugated MEK1/2 kinase inhibitors for integrin-targeted cancer therapy. Molecules. 2013;18(11):13957-78.
134. Cao Q, Li ZB, Chen K, Wu Z, He L, Neamati N, et al. Evaluation of biodistribution and anti-tumor effect of a dimeric RGD peptide-paclitaxel conjugate in mice with breast cancer. Eur J Nucl Med Mol Imaging. 2008;35(8):1489-98.
135. Chen X, Plasencia C, Hou Y, Neamati N. Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery. J Med Chem. 2005;48(4):1098-106.
136. Kim JW, Lee HS. Tumor targeting by doxorubicin-RGD-4C peptide conjugate in an orthotopic mouse hepatoma model. Int J Mol Med. 2004;14(4):529-35.
137. Lelle M, Frick SU, Steinbrink K, Peneva K. Novel cleavable cell-penetrating peptide-drug conjugates: synthesis and characterization. J Pept Sci. 2014;20(5):323-33.
138. Rothbard JB, Garlington S, Lin Q, Kirschberg T, Kreider E, McGrane PL, et al. Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation. Nat Med. 2000;6(11):1253-7.
139. Miyaji Y, Walter S, Chen L, Kurihara A, Ishizuka T, Saito M, et al. Distribution of KAI-9803, a novel delta-protein kinase C inhibitor, after intravenous administration to rats. Drug Metab Dispos. 2011;39(10):1946-53.
140. Shi NQ, Gao W, Xiang B, Qi XR. Enhancing cellular uptake of activable cell-penetrating peptide-doxorubicin conjugate by enzymatic cleavage. Int J Nanomedicine. 2012;7:1613-21.
141. Meyer-Losic F, Nicolazzi C, Quinonero J, Ribes F, Michel M, Dubois V, et al. DTS-108, a novel peptidic prodrug of SN38: in vivo efficacy and toxicokinetic studies. Clin Cancer Res. 2008;14(7):2145-53.
142. Kurzrock R, Gabrail N, Chandhasin C, Moulder S, Smith C, Brenner A, et al. Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors. Mol Cancer Ther. 2012;11(2):308-16.
143. Yang RC, Huang JT, Chen YL, Hung CC, Liao M, Yao WC, et al. Enthalpy-driven nuclease-like activity and mechanism of peptide-chlorambucil conjugates. Org Biomol Chem. 2014;12(27):4890-904.
144. Majumdar S, Kobayashi N, Krise JP, Siahaan TJ. Mechanism of internalization of an ICAM-1-derived peptide by human leukemic cell line HL-60: influence of physicochemical properties on targeted drug delivery. Mol Pharm. 2007;4(5):749-58.
145. Tai W, Shukla RS, Qin B, Li B, Cheng K. Development of a peptide-drug conjugate for prostate cancer therapy. Mol Pharm. 2011;8(3):901-12.
146. Lin N, Schwartzberg L, Kesari S, Yardley D, Verma S, Anders C, et al. Abstract P3-12-04: A phase 2, multi-center, open label study evaluating the efficacy and safety of GRN1005 alone or in combination with trastuzumab in patients with brain metastases from breast cancer. Cancer Res. 2012;72(24 Supplement):3. 12-04.
147. Liu L, Ye Q, Lu M, Lo YC, Hsu YH, Wei MC, et al. A new approach to reduce toxicities and to improve bioavailabilities of platinum-containing anti-cancer nanodrugs. Sci Rep. 2015;5:10881.